Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD - University of the Witwatersrand, Johannesburg, South Africa

Educational information

This video was recorded during the virtual 2020 EAS Congress.

Faculty

Professor Frederick Raal is Professor and Head of the Division of Endocrinology and Metabolism at the University of the Witwatersrand, Johannesburg, South Africa.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of this analysis

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.